Key result
Multimodal imaging and genetics improve cardiac myxoma diagnosis and personalized surgery, requiring long-term follow-up.
Why the study?
Despite its benign histologic nature, cardiac myxoma can cause severe clinical consequences due to its anatomical location and potential for embolization.
This review summarizes current knowledge on cardiac myxoma, emphasizing the role of multimodal imaging, molecular genetics, and the necessity of long-term follow-up.
Alerts to embolization risks in cardiac myxoma; leaves open PRKAR1A-targeted therapies for prospective study.
Cardiac myxoma is the most common primary benign cardiac neoplasm. Despite its benign histologic nature, its unique anatomical location and potential for embolization can lead to severe clinical consequences. This article reviews the epidemiological characteristics, pathological features, and molecular genetic mechanisms of cardiac myxoma—particularly mutations in the PRKAR1A gene (encoding the type 1α regulatory subunit of cyclic adenosine monophosphate–dependent protein kinase A) and the stem cell origin hypothesis. Furthermore, it discusses clinical presentation, multimodal imaging, diagnostic approaches, and recent advances in surgical management. While improvements in imaging technology and a deeper understanding of molecular mechanisms have significantly enhanced early diagnosis and personalized treatment, long-term follow-up remains a critical component of clinical management, particularly for familial cases.
No takes yet. Share an insight, caveat, or question.
Tusongjiang et al. (2026) conducted a review in Cardiac myxoma. Advances in multimodal imaging and molecular genetics have enhanced the early diagnosis and personalized surgical management of cardiac myxoma, though long-term follow-up remains critical.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: